Clinical trials: EGFR
Non-small Cell Lung Cancer (NSCLC)
A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT)
The main aim of this study is to examine the percentage of people with lung cancer who carry a certain gene mutation (epidermal growth factor receptor exon 20 insertions - EGFR ex20ins) and their frequency in Chinese participants…
- Trial name
- ELEGANT (NCT05737849)
- Testing
- No Intervention
- Where
- China
- Sponsor
- Takeda
Lung Cancer, Breast Cancer
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
- Trial name
- NCT06618287
- Testing
- BMS-986507, Osimertinib, Pembrolizumab
- Where
- 65 sites in United States, Australia and 8 more
- Volunteers
- 416 people
- Sponsor
- Bristol-Myers Squibb
Penile Cancer
MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma
Penile squamous cell carcinoma (PSCC) is a rare malignancy, with stage IV patients exhibiting a 2-year overall survival (OS) rate of 21% and a 5-year survival rate of 0%.
- Trial name
- MH-Penile-001 (NCT07054307)
- Testing
- MRG003, HX008
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jiyan Liu
Breast Cancer
RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
This is a retrospective, observational study that will document treatment patterns and clinical outcomes of postmenopausal patients diagnosed with HR+/HER2- mBC who received Palbociclib plus Letrozole as initial endocrine-based…
- Trial name
- NCT04460898
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer (NSCLC)
e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer
The purpose of this study is to develop a real-time diagnostic technique with e- Ab sensor for specific EGFR mutation detection in clinical specimens of NSCLC patients, the investigators conduct a prospective clinical study.
- Trial name
- NCT01359436
- Testing
- Electrosensing antibody probing system (e- Ab sensing)
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Neoplasms
Study of IMC-11F8 in Participants With Advanced Solid Tumors
This study is to establish the safety and pharmacokinetic (PK) profile of IMC-11F8, administered either: (1) in a 3-week cycle; or (2) in a 2-week cycle to Japanese participants with advanced solid tumors who have not responded…
- Trial name
- NCT01088464
- Testing
- IMC-11F8
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib
Recently it has been suggested that specific mutations in the EGFR gene in lung cancer patients is associated with response to a novel drug targeting the EGF system.
- Trial name
- NCT00815971
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Aarhus University Hospital
EGFR Mutation Status in aNSCLC Patients
Asia Pacific and Russia Diagnostic Study for EGFR Testing
Interventional diagnostic, international, multicenter and non-comparative study of EGFR mutation status in aNSCLC patients (locally advanced and/or metastatic disease) with adenocarcinoma and non-adenocarcinoma histologies.
- Trial name
- IGNITE (NCT01788163)
- Testing
- EGFR mutation test
- Where
- 71 sites in Australia, China and 7 more
- Volunteers
- 3,500 people
- Sponsor
- AstraZeneca
NSCLC Stage IV Without EGFR/ALK Mutation
Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
This study aims to conduct a prospective, multicenter, umbrella clinical study to compare the abscopal effects of different radiotherapy fractionation patterns combined with Benmelstobart, and to explore an efficient and…
- Trial name
- NCT06953843
- Testing
- Benmelstobart combined with chemotherapy, Benmelstobart combined with Bevacizumab and chemotherapy
- Where
- China
- Volunteers
- 366 people
- Sponsor
- Xinqiao Hospital of Chongqing
Stomach Neoplasms
Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma
In this open-label, single-center, small sample size, randomised, parallel-group, controlled study, the investigators aim to assess efficacy and safety of addition of nimotuzumab to CS chemotherapy in patients with previously…
- Trial name
- NCT02370849
- Testing
- nimotuzumab, cisplatin, S-1
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Chinese Academy of Medical Sciences
Lupus Nephritis
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)
The purpose of this study was to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients with active lupus nephritis (LN).
- Trial name
- NCT05781750
- Testing
- zetomipzomib
- Where
- 50 sites in United States, Argentina and 10 more
- Volunteers
- 84 people
- Sponsor
- Kezar Life Sciences, Inc.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer
This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metastatic non-small cell lung…
- Trial name
- NCT04448379
- Testing
- JMT101
- Where
- 13 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai JMT-Bio Inc.
Lung Cancer, Non Small Cell Lung Cancer
Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC
The purpose of this study is to evaluate the safety and clinical activity of Apatinib in combination with AP(Pemetrexed/Carboplatin) or AC(Pemetrexed/Carboplatin) as first-line chemotherapy in subjects with advanced EGFR wild…
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Combination Chemotherapy, Apatinib
- Trial name
- NCT03201146
- Testing
- Apatinib, AP or AC, Apatinib 250mg
- Where
- China
- Volunteers
- 48 people
- Sponsor
- West China Hospital
Breast Cancer
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
This is a randomized, double-blind, multicenter trial，parallel control designed to evaluate treatment with trastuzumab + QL1209 + docetaxel compared with trastuzumab + pertuzumab + docetaxel in the participants with early-stage…
- Trial name
- NCT04629846
- Testing
- Trastuzumab, QL1209, Pertuzumab
- Where
- 2 sites in China
- Volunteers
- 517 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Neoplasms, Breast
GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer
This is two-part study (Phase I/Phase II). Part I is designed to find the optimal (best) doses of GW572016 and trastuzumab when given together,Part II is designed to evaluate the tumor response rate (shrinkage or lack of growth)…
- Trial name
- NCT00371488
- Testing
- GW572016 oral tablets
- Where
- 2 sites in Japan
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Cancer
Effects of a Visual Interactive LINE Chatbot on Self-Management of EGFR-TKI Related Side Effects in Patients With Lung Cancer
This study aims to evaluate a visual interactive LINE chatbot designed to support self-management of treatment-related side effects among patients with advanced lung cancer receiving epidermal growth factor receptor-tyrosine…
- Trial name
- NCT07310589
- Testing
- Visual-Interactive LINE Chatbot
- Volunteers
- 178 people
- Sponsor
- National Taiwan University Hospital
Endometrial Cancer
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample.
- Trial name
- Fern-EC-01 (NCT06340568)
- Testing
- BNT323/DB-1303, Doxorubicin, Paclitaxel
- Where
- 206 sites in United States, Argentina and 25 more
- Volunteers
- 480 people
- Sponsor
- BioNTech SE
Breast Neoplasms
A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting
The study is descriptive and aims to characterize the treatment patterns of advanced breast cancer in Poland in the real-world data setting.
- Trial name
- NCT05478590
- Where
- 19 sites in Poland
- Volunteers
- 440 people
- Sponsor
- Pfizer
Renal Allograft Recipients
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
The purpose of this study is to evaluate the benefits and risks of conversion of existing adolescent kidney allograft recipients aged 12 to less than 18 years of age to a belatacept-based immunosuppressive regimen as compared to…
- Trial name
- NCT04877288
- Testing
- Belatacept, Tacrolimus, Cyclosporine A
- Where
- 38 sites in United States, Argentina and 8 more
- Volunteers
- 102 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer
Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients
The main objective of this study is to evaluate the safety and tolerability of HM61713.
- Trial name
- NCT01588145
- Testing
- HM61713
- Where
- South Korea
- Volunteers
- 273 people
- Sponsor
- Hanmi Pharmaceutical Company Limited